BioLife Sciences Inc. (OTC Markets: BLFE) Signs LOI with Health Box LLC Towards the 100% Acquisition of the Arizona, USA Based Entity Specializing in Advanced Orthomolecular Medicine and Natural Health Products Development and Research
25 Janeiro 2022 - 6:42PM
InvestorsHub NewsWire
Toronto, Ontario, Canada -- January 25, 2022 -- InvestorsHub
NewsWire -- BioLife Sciences (OTCPK
: BLFE) is pleased to announce that it has entered into
exclusive negotiations with Health Box LLC, an Arizona-based
company which provides a diverse mix of advanced orthomolecular and
natural health products founded in -- extensive research focused on
medicinal botanicals, micronutrients, dietary supplements,
proprietary herbal blends, and apothecary style subscription
services.
With this contemplated acquisition, BioLife Sciences would be
provided with a synergistic opportunity to expand its current
healthcare product offerings into a brand-new product line of
advanced orthomolecular and natural health products & solutions
with a focus on (but not limited to): gastrointestinal health,
endocrine health, cardiovascular health, immune health, specialty
health, musculoskeletal health, and men’s/women’s health. Health
Box LLC also specializes in the development of tinctures, oils,
vitamins and hemp-derived cannabidiol (CBD) products.
Health Box LLC began its operations in 2018 and has quickly
increased its market share in the highly competitive orthomolecular
industry.
“An acquisition of Health Box LLC would position BioLife
Sciences as a disruptive entity within a booming market. The
company would become uniquely positioned to reach consumers who are
seeking safe, natural, holistic approaches towards proactive
self-care and treating or preventing certain symptoms and illnesses
through the use of natural supplements. Health Box
LLC would offer the company instant access to meaningful revenue,
an existing customer base, subject matter expertise, and innovative
breakthroughs,” Mr. De Four said.
“The COVID-19 pandemic has given consumers heightened
awareness of medicinal botanicals and supplements which were
traditionally overlooked, especially those that boost immunity.
This is a defining moment in BioLife Sciences’ transformation
towards driving sustainable growth, revenue diversification and
creating increased value for all stakeholders.”
The global herbal supplements market is projected to reach 86.74
billion (USD) by 2022 with a CAGR of 6.8% from 2016 to 2022. Single
herb supplements grew by 14.5% in 2020 while combination-herb
supplements grew by 24.7%. This growth was driven by supplements
which addressed immunity, sleep support, and brain health, as well
as mood and mental wellness, with those categories growing by
30%.
About BioLife Sciences Inc.
BioLife Sciences Inc. specializes in moving innovative products
from the lab or small-scale production into wider market adoption.
Its core business develops, licenses and distributes antimicrobial
products and disruptive technology. One of BioLife Sciences’ core
building block strategies is to develop, partner and assist
innovative companies with the commercialization of leading-edge
technologies.
About Health Box LLC
Health Box LLC offers advanced, high-quality, orthomolecular
medicine including micronutrients, medicinal herbal supplements,
botanicals and holistic merchandises. The company also specializes
in hemp sourced CBD and introduced the first CBD subscription
health box to the United States market.
Disclaimer
The information in this news release includes certain
information and statements about management's view of future
events, expectations, plans and prospects that constitute forward
looking statements. These statements are based upon assumptions
that are subject to significant risks and uncertainties. Because of
these risks and uncertainties and as a result of a variety of
factors, the actual results, expectations, achievements or
performance may differ materially from those anticipated and
indicated by these forward-looking statements. Forward-looking
statements in this news release include, but are not limited to,
the ability of the Corporation to complete a qualifying
transaction. Any number of factors could cause actual results to
differ materially from these forward-looking statements as well as
future results. Although the Corporation believes that the
expectations reflected in forward looking statements are
reasonable, it can give no assurance that the expectations of any
forward-looking statements will prove to be correct. Except as
required by law, the Corporation disclaims any intention and
assumes no obligation to update or revise any forward-looking
statements to reflect actual results, whether as a result of new
information, future events, changes in assumptions, changes in
factors affecting such forward-looking statements or otherwise.
Contact Information:
www.biolifesciences.com
ir@biolifesciences.com
US & Canada: 1 (833) 919-1037
BioLife Sciences (CE) (USOTC:BLFE)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
BioLife Sciences (CE) (USOTC:BLFE)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024